- Home
- EAF vs TRVI Comparison
EAF vs TRVI Comparison
Compare EAF & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EAF
- TRVI
- Stock Information
- Founded
- EAF 1886
- TRVI 2011
- Country
- EAF United States
- TRVI United States
- Employees
- EAF N/A
- TRVI N/A
- Industry
- EAF Industrial Machinery/Components
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- EAF Energy
- TRVI Health Care
- Exchange
- EAF Nasdaq
- TRVI Nasdaq
- Market Cap
- EAF 437.2M
- TRVI 363.7M
- IPO Year
- EAF 1995
- TRVI 2019
- Fundamental
- Price
- EAF $1.24
- TRVI $4.60
- Analyst Decision
- EAF Hold
- TRVI Strong Buy
- Analyst Count
- EAF 5
- TRVI 8
- Target Price
- EAF $1.73
- TRVI $9.31
- AVG Volume (30 Days)
- EAF 4.2M
- TRVI 739.7K
- Earning Date
- EAF 02-07-2025
- TRVI 03-19-2025
- Dividend Yield
- EAF N/A
- TRVI N/A
- EPS Growth
- EAF N/A
- TRVI N/A
- EPS
- EAF N/A
- TRVI N/A
- Revenue
- EAF $538,782,000.00
- TRVI N/A
- Revenue This Year
- EAF $5.45
- TRVI N/A
- Revenue Next Year
- EAF $20.62
- TRVI N/A
- P/E Ratio
- EAF N/A
- TRVI N/A
- Revenue Growth
- EAF N/A
- TRVI N/A
- 52 Week Low
- EAF $0.52
- TRVI $2.30
- 52 Week High
- EAF $2.53
- TRVI $5.05
- Technical
- Relative Strength Index (RSI)
- EAF 43.54
- TRVI 62.80
- Support Level
- EAF $1.01
- TRVI $3.93
- Resistance Level
- EAF $1.34
- TRVI $4.14
- Average True Range (ATR)
- EAF 0.14
- TRVI 0.29
- MACD
- EAF -0.01
- TRVI 0.06
- Stochastic Oscillator
- EAF 35.61
- TRVI 64.82
About EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two major product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.